Daclatasvir Medications

Daclatasvir is a direct-acting antiviral agent used to treat chronic hepatitis C virus infection. It works by interfering with viral RNA replication.

Daklinza

Daclatasvir

$14.00 per pill

60mg

Select pack

About Daclatasvir

Daclatasvir is an antiviral agent classified as an NS5A inhibitor, a key component of modern direct-acting regimens for chronic hepatitis C virus (HCV) infection. By binding to the NS5A protein, it disrupts viral RNA replication and assembly, leading to rapid declines in viral load. The drug is marketed under several brand names, including Daklinza, and is widely available in generic form through our online pharmacy. While its primary indication is the treatment of genotype-1, 2, 3, and 4 HCV infections, clinicians also employ it in combination with other direct-acting agents for broader genotype coverage. Off-label, it has been explored in experimental protocols for hepatitis B co-infection, though such use remains investigational. The safety profile, highlighted by the absence of severe hepatotoxicity, makes Daclatasvir a cornerstone of interferon-free HCV therapy, offering a well-tolerated option for adults seeking cure.

What is Daclatasvir?

Daclatasvir belongs to the class of selective NS5A inhibitors, a subset of direct-acting antivirals (DAAs) that target a non-structural protein essential for hepatitis C replication. The Therapeutic Goods Administration (TGA) of Australia approved the drug in 2015 following a joint assessment with the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Initially indicated for genotype-1 HCV infection, subsequent label expansions-recorded by the FDA in 2016-added genotype-2 through 4, reflecting its broad antiviral activity when paired with complementary agents such as sofosbuvir. Mechanistically, Daclatasvir binds to the membrane-associated NS5A domain, hindering the formation of the replication complex and interrupting virion assembly. Both patented formulations and cost-effective generics are stocked by our pharmacy service, ensuring access without compromising quality.

How Daclatasvir Works

Mechanism of Action

Daclatasvir targets the HCV NS5A protein, an essential scaffold that coordinates viral RNA synthesis and particle formation. By occupying a hydrophobic pocket within NS5A, the drug forces conformational changes that prevent the protein from anchoring to host cell membranes. This blockade halts the production of new viral genomes, leading to a swift reduction in circulating HCV RNA. The Daclatasvir mechanism of action is confirmed in peer-reviewed studies published in The New England Journal of Medicine and Lancet Infectious Diseases.

Therapeutic Effects

The interruption of NS5A activity translates into a marked decline in viral load, often exceeding a 4-log reduction within the first week of therapy. When combined with a nucleotide polymerase inhibitor such as sofosbuvir, the regimen achieves sustained virologic response (SVR) rates above 95 % across most genotypes. Clinically, patients experience normalization of liver enzymes, reduced hepatic inflammation, and a dramatically lowered risk of progression to cirrhosis or hepatocellular carcinoma.

Onset and Duration

Clinical trials indicate that the antiviral effect of Daclatasvir begins within 48 hours of the first dose, with peak plasma concentrations reached at approximately 2 hours post-administration. The drug’s half-life, averaging 12-15 hours, supports once-daily dosing. Full treatment courses typically span 8-12 weeks, depending on genotype, baseline viral load, and the presence of cirrhosis. The question “how long does Daclatasvir take to work” is answered by these data: measurable viral decline occurs within days, while cure (SVR12) is confirmed 12 weeks after treatment completion.

Approved Uses and Applications

Approved Indications

Genotype 1 HCV infection - Daclatasvir combined with sofosbuvir (or velpatasvir) is indicated for treatment-naïve and treatment-experienced adults, as per the TGA label.
Genotype 2, 3, 4 infections - When paired with sofosbuvir, the regimen is approved for 12-week courses in patients without cirrhosis and 24-week courses in compensated cirrhosis (FDA, 2016).
HIV-HCV co-infection - The combination is listed as safe and effective in co-infected adults, provided antiretroviral regimens do not contain strong CYP3A4 inducers.

Off-Label Uses

Daclatasvir has been investigated in small phase II studies as part of dual therapy for hepatitis B virus (HBV) suppression, but regulatory bodies in Australia and the United States have not granted approval for this indication. Consequently, Daclatasvir is not officially recommended for HBV management.

Clinical Efficacy

A pivotal Phase III trial (ALLY-3) published in Lancet reported a 96 % SVR12 rate in genotype-3 patients receiving Daclatasvir + sofosbuvir for 12 weeks. The ALLY-1 study demonstrated a 99 % SVR12 rate among genotype-1 patients with compensated cirrhosis treated for 12 weeks. These outcomes underscore Daclatasvir’s high cure potential across diverse patient populations.

Buying Daclatasvir from Our Online Pharmacy

Why Choose Our Service

Access to Daclatasvir can be limited in regional Australia due to supply chain constraints. Our online pharmacy bridges that gap, offering a discreet and reliable channel to obtain both brand-name and generic formulations. Secure ordering, verified sourcing, and compliance with Australian regulatory standards guarantee a safe purchase experience.

Brand Names and Generic Options

Daklinza - the approved brand product, priced competitively through bulk sourcing.
Generic Daclatasvir - manufactured by WHO-GMP-certified facilities, delivering the same 60 mg tablet at a lower cost.
Combination packs - pre-filled packages that pair Daclatasvir with sofosbuvir, simplifying regimen adherence.

Quality & Safety

We partner with licensed international pharmacies that adhere to WHO standards and undergo regular audits by the TGA. All batches are accompanied by batch-specific certificates of analysis, ensuring potency and purity.

Pricing & Access

Generic Daclatasvir tablets are offered at a 30 % discount compared with brand pricing. Reorder customers receive a Lifetime 10 % discount on all future purchases, making long-term therapy financially sustainable.

Discreet Delivery

Orders shipped via our service arrive in unmarked packaging. Express delivery averages 7 days within major Australian cities, while Standard shipping reaches remote locations within 3 weeks.

Dosing, Formulations & Administration

Available Formulations

Daclatasvir is supplied as 60 mg oral tablets. Some combination kits include a 400 mg sofosbuvir tablet for fixed-dose therapy. No liquid or injectable forms are currently marketed.

Typical Dosing Ranges

For HCV genotype-1 infection, clinicians often initiate therapy with a single 60 mg tablet of Daclatasvir once daily, combined with a 400 mg tablet of sofosbuvir. In genotype-3 patients with cirrhosis, the regimen may be extended to 24 weeks, maintaining the same daily dose. Dosage adjustments are rarely required because renal clearance is minimal, but hepatic impairment may prompt closer monitoring.

Administration Guidelines

Daclatasvir tablets should be taken with a glass of water, with or without food; studies show food does not significantly affect absorption. Patients should avoid co-administration of strong CYP3A4 inducers such as rifampicin, as these can lower drug exposure. Consistent daily timing improves adherence and therapeutic consistency.

Note: The exact dose and treatment length must be individualized by a qualified healthcare professional after evaluating liver function, viral genotype, and potential drug interactions.

Safety Profile & Considerations

Common Side Effects

Fatigue - reported in ~15 % of participants (ALLY-3).
Headache - observed in 12-14 % of users.
Nausea - occurred in roughly 10 % of patients.
Diarrhea - documented in 8-10 % of trial subjects.

These events are typically mild to moderate and resolve without discontinuation.

Serious Adverse Events

Rarely, patients experience elevated hepatic enzymes (>5 × ULN) or severe allergic reactions. Immediate medical evaluation is warranted if jaundice, dark urine, or rash develops.

Contraindications

Severe hepatic impairment (Child-Pugh C) - Daclatasvir is not recommended due to insufficient safety data.
Concurrent use of strong CYP3A4 inducers - agents such as carbamazepine, phenytoin, and efavirenz markedly reduce drug exposure and are contraindicated.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can increase Daclatasvir plasma levels, potentially heightening toxicity.
Other NS5A inhibitors - co-administration may lead to additive antiviral effects but requires specialist oversight.
Antiretrovirals - certain protease inhibitors (e.g., ritonavir-boosted regimens) may alter Daclatasvir concentrations; dose adjustments may be needed.

Special Populations

Pregnancy & Breastfeeding - Limited human data exist; the TGA advises avoidance unless the benefit outweighs potential risk.
Older Adults - No dose reduction is required, but clinicians should monitor liver function closely.
Renal Impairment - No dose adjustment is necessary because the drug is minimally renally excreted.
Hepatic Impairment - Mild to moderate impairment does not necessitate change, yet severe disease mandates specialist review.

Frequently Asked Questions

What is the Daclatasvir mechanism of action? Daclatasvir binds to the NS5A protein, disrupting the formation of the viral replication complex and preventing hepatitis C RNA synthesis and virion assembly.
How does Daclatasvir differ from sofosbuvir? While Daclatasvir targets the NS5A scaffold, sofosbuvir is a nucleotide analogue that inhibits the viral RNA-dependent RNA polymerase (NS5B). Using both drugs together attacks the virus at two distinct stages, boosting cure rates.
How long before Daclatasvir produces noticeable effects for hepatitis C? Viral load reductions are measurable within 48 hours; however, the clinical endpoint of cure (SVR12) is confirmed 12 weeks after the end of therapy.
What should I do if I experience persistent headache while taking Daclatasvir? Most headaches are mild and transient. If the symptom persists beyond a few days or worsens, contact a healthcare provider to rule out other causes.
Can I take Daclatasvir with food? Yes. Food does not significantly alter absorption, so the tablet can be taken with or without meals.
Are there any foods I should avoid while on Daclatasvir? No specific dietary restrictions are required, but grapefruit juice can modestly increase CYP3A4 activity and should be avoided if you are also on a CYP3A4 inhibitor.
What are the most serious side effects that require emergency care? Signs of severe liver injury (jaundice, dark urine, right-upper-quadrant pain) or an allergic reaction (rash, swelling, difficulty breathing) should prompt immediate medical attention.
Does Daclatasvir interact with common over-the-counter supplements? St. John’s wort, a strong CYP3A4 inducer, can reduce Daclatasvir levels and should be avoided. Other supplements generally pose low risk but discuss all products with your clinician.
Is Daclatasvir safe for older adults? The drug has been studied in patients up to 80 years old without requiring dose changes, though liver function should be assessed before initiation.
What information should I provide my doctor when discussing Daclatasvir?
- Complete list of current prescription medicines, over-the-counter drugs, and supplements.
- History of liver disease, including any prior hepatitis C treatments.
- Presence of any known CYP3A4 inducers or inhibitors in your regimen.
- Pregnancy status or plans for conception, if applicable.

Disclaimer

The information provided about Daclatasvir is for general knowledge only. It does not replace professional medical consultation or the official prescribing information for medications containing this ingredient. All treatment decisions, including dosing, formulation selection, and monitoring, should be made under the supervision of a qualified healthcare provider who can assess individual medical history, current medications, and specific health needs. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to medications containing Daclatasvir for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication containing Daclatasvir.